American Society of Ketamine Physicians

American Society of Ketamine Physicians The group is for ASKP3 members to connect, share and grow in the ketamine community.

⏰ Last Chance to Join Us LiveThere’s still time to register for ASKP3’s Meet the Expert webinar:Ketamine With Other Medi...
03/20/2026

⏰ Last Chance to Join Us Live

There’s still time to register for ASKP3’s Meet the Expert webinar:

Ketamine With Other Medicines, Supplements, and Psychedelics
📅 Monday, March 23, 2026
⏰ 8:30 p.m. ET

Join Michael Mantz, MD, MH as he explores how ketamine interacts with medications, supplements, and psychedelics—bringing together clinical insight, integrative medicine, and real-world application.

This session is designed to help you:
✔ Navigate complex treatment considerations
✔ Explore emerging research
✔ Gain practical, patient-centered insights

🎥 Plus, all registrants receive on-demand access for one year

Free for ASKP3 members | Non-members: $35

👉 Save your spot now: https://askp.org/meet-the-expert/

What happens when ketamine meets supplements, prescriptions, or psychedelics?Join ASKP3’s Meet the Expert webinar on Mon...
03/04/2026

What happens when ketamine meets supplements, prescriptions, or psychedelics?

Join ASKP3’s Meet the Expert webinar on Monday, March 23, 2026, at 8:30 p.m. ET for a thoughtful and clinically grounded exploration of:

Ketamine With Other Medicines, Supplements, and Psychedelics

Led by Dr. Michael Mantz, MD, MH, this session dives into real-world considerations, emerging research, and nuanced clinical insights around combining ketamine with other substances.

This free webinar for ASKP3 members offers:
✔ Expert-led discussion
✔ Practical takeaways for clinical application
✔ On-demand access for one full year

Not a member yet? Non-members can attend for $35 USD.

If you’re working in ketamine-assisted therapy or integrative psychiatry, this is a conversation you won’t want to miss.

👉 Register now: https://askp3.memberclicks.net/index.php?option=com_mcform&view=ngforms&id=2270706 #/

02/01/2026

Moments from the ASKP3 Annual Conference.
Speakers sharing their work and experience. We are so grateful for this community.

🧠 Session Highlight: IV Esketamine and Suicidal Ideation in Real-World CareControlled trials show ketamine’s rapid anti-...
01/23/2026

🧠 Session Highlight: IV Esketamine and Suicidal Ideation in Real-World Care

Controlled trials show ketamine’s rapid anti-suicidal effects — but how does it perform in everyday clinical practice? This session examines real-world outpatient data demonstrating significant reductions in suicidal ideation after a single IV esketamine infusion, with benefits sustained for up to three months in patients continuing maintenance treatment.

Unless you’ve been directed otherwise, please list the speakers in alpha order by last name in all three SM posts.

Presented by Margot Kades, Brittany O’Brien, PhD, and Tiago Gil, MD, the study offers valuable insight into durability, clinical monitoring, and the role of IV esketamine beyond controlled research settings.

Join us to explore data that can inform clinical decision-making and improve care for high-risk patients — and hear additional sessions from Dr. O’Brien and Dr. Gil during the Conference.

👉 Register now and join us at .
https://askp3.memberclicks.net/2026annual #/

In just days, clinicians, researchers, and innovators gather to move care forward, together.📅 January 29–31, 2026📍 Austi...
01/22/2026

In just days, clinicians, researchers, and innovators gather to move care forward, together.

📅 January 29–31, 2026
📍 Austin, TX

⏰ Final Call for Exhibitors & SponsorsThe ASKP3 2026 Annual Conference is almost here, and exhibitor and sponsor spaces ...
01/22/2026

⏰ Final Call for Exhibitors & Sponsors

The ASKP3 2026 Annual Conference is almost here, and exhibitor and sponsor spaces are nearly gone. This is your last opportunity to place your brand in front of the clinicians, researchers, and innovators shaping the future of ketamine therapy and psychedelic-assisted care.

If your organization supports this work, Austin is where you need to be. Don’t miss the chance to connect with decision-makers, elevate your visibility, and build meaningful partnerships.

📅 January 29–31, 2026
📍 Austin Marriott Downtown

Secure your booth or sponsorship now before spaces are gone!
https://askp3.memberclicks.net/ASKP3Annual26Exhibitors #/

🧠 Session Highlight: Ketamine’s Neuroplastic EdgeKetamine is more than a rapid-acting antidepressant — it’s a powerful n...
01/21/2026

🧠 Session Highlight: Ketamine’s Neuroplastic Edge

Ketamine is more than a rapid-acting antidepressant — it’s a powerful neuropathogenic that opens a critical window for brain change. In this session, Dr. Nicholas Mischel, Assistant Professor of Psychiatry at Wayne State University, explores how ketamine’s unique neuroplastic effects can be strategically integrated with neuromodulation platforms such as TMS, ECT, and CES.

Learn how these synergistic approaches may optimize treatment outcomes and support more personalized, comprehensive mental health care for complex patients.

👉 Register now and join us at ASKP3 2026 to explore what’s next in interventional psychiatry.
https://askp3.memberclicks.net/2026annual #/

The conversations shaping what’s next start here.January 29–31, 2026 · Austin, TX
01/19/2026

The conversations shaping what’s next start here.
January 29–31, 2026 · Austin, TX

𝗣𝗿𝗼𝗴𝗿𝗲𝘀𝘀 doesn’t knock.It 𝗯𝗿𝗲𝗮𝗸𝘀 through.Built 𝘁𝗵𝗿𝗼𝘂𝗴𝗵 collaboration, rigor, and purpose.𝗔𝗦𝗞𝗣𝟯 𝗔𝗻𝗻𝘂𝗮𝗹 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝟮𝟬𝟮𝟲Jan...
01/16/2026

𝗣𝗿𝗼𝗴𝗿𝗲𝘀𝘀 doesn’t knock.
It 𝗯𝗿𝗲𝗮𝗸𝘀 through.
Built 𝘁𝗵𝗿𝗼𝘂𝗴𝗵 collaboration, rigor, and purpose.

𝗔𝗦𝗞𝗣𝟯 𝗔𝗻𝗻𝘂𝗮𝗹 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝟮𝟬𝟮𝟲
January 29–31 · Austin, TX

🧠 Session Highlight: Oral Ketamine in Dementia CareAt the 2026 ASKP3 Annual Conference, Lucinda Grande, MD, FASAM, will ...
01/16/2026

🧠 Session Highlight: Oral Ketamine in Dementia Care
At the 2026 ASKP3 Annual Conference, Lucinda Grande, MD, FASAM, will present outcomes from a small but thought-provoking treatment trial of daily sub-dissociative oral ketamine in older adults with mild to advanced dementia.

In this case series of patients ages 69–89, several individuals showed improvements in mood, activity level, and cognition after one month, as reported by family members and supported by standardized cognitive testing. While conclusions are necessarily cautious, the findings raise important questions about ketamine’s potential role in geriatric and neurocognitive care.

Join us to explore the data, clinical considerations, and implications for future research — and hear Dr. Grande’s additional session on ketamine-assisted buprenorphine initiation from fentanyl.

👉 Register now and join the conversation in Austin.
https://askp3.memberclicks.net/2026annual

This is how progress actually happens: through conversation, collaboration, and shared purpose.January 29–31, 2026 · Aus...
01/14/2026

This is how progress actually happens: through conversation, collaboration, and shared purpose.

January 29–31, 2026 · Austin, TX

Address

222 S. Westmonte Drive, Suite 111
Altamonte Springs, FL
32714

Opening Hours

Monday 8:30am - 5pm
Tuesday 8:30am - 5pm
Wednesday 8:30am - 5pm
Thursday 8:30am - 5pm
Friday 8:30am - 5pm

Website

Alerts

Be the first to know and let us send you an email when American Society of Ketamine Physicians posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to American Society of Ketamine Physicians:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category